Empfehlung
13,7
Stark Verkaufen
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)
Score-Verlauf (90 Tage)
Stammdaten
Unternehmen
| Name | Karyopharm Therapeutics Inc. |
|---|---|
| Ticker | KPTI |
| CIK | 0001503802 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Karyopharm Therapeutics Inc. |
Status
| Zuletzt geprüft | 2026-03-20 22:38:15.180483 |
|---|
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 146,067,000 | -196,039,000 | -17.93 | 108,416,000 | -292,926,000 |
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Abate Kristin | Officer, Chief Accounting Officer | Open Market Sale | -559 | 9.41 | -5,259.91 | -15,3% | |
| 2026-03-02 | Cheng Sohanya Roshan | Officer, EVP & Chief Commercial Officer | Open Market Sale | -4,604 | 9.41 | -43,321.34 | -126,3% | |
| 2026-03-02 | Cheng Sohanya Roshan | Officer, EVP & Chief Commercial Officer | Open Market Sale | -4,604 | 9.41 | -43,321.34 | -126,3% | |
| 2026-03-02 | Poulton Stuart | Officer, EVP, Chief Development Officer | Open Market Sale | -5,101 | 9.41 | -47,997.86 | -140,0% | |
| 2026-03-02 | Rangwala Reshma | Officer, EVP & Chief Medical Officer | Open Market Sale | -5,066 | 9.41 | -47,668.53 | -139,0% | |
| 2026-03-02 | Mano Michael | Officer, EVP, CLO&Secretary | Open Market Sale | -3,526 | 9.41 | -33,177.90 | -96,7% | |
| 2026-03-02 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -12,361 | 9.41 | -116,310.83 | -339,1% | |
| 2026-03-02 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -12,361 | 9.41 | -116,310.83 | -339,1% | |
| 2026-03-02 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -12,361 | 9.41 | -116,310.83 | -339,1% | |
| 2026-03-02 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -12,361 | 9.41 | -116,310.83 | -339,1% | |
| 2025-09-15 | Cheng Sohanya Roshan | Officer, EVP & Chief Commercial Officer | Open Market Sale | -325 | 6.43 | -2,089.75 | -6,1% | |
| 2025-09-15 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -1,257 | 6.43 | -8,082.51 | -23,6% | |
| 2025-09-15 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -1,257 | 6.43 | -8,082.51 | -23,6% | |
| 2025-09-15 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -1,257 | 6.43 | -8,082.51 | -23,6% | |
| 2025-09-03 | Abate Kristin | Officer, Chief Accounting Officer | Open Market Sale | -12 | 6.78 | -81.36 | -0,2% | |
| 2025-05-06 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -236 | 7.12 | -1,680.32 | -4,9% | |
| 2025-05-06 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -236 | 7.12 | -1,680.32 | -4,9% | |
| 2025-05-06 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -236 | 7.12 | -1,680.32 | -4,9% | |
| 2025-04-04 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -245 | 3.74 | -916.30 | -2,7% | |
| 2025-04-04 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -245 | 3.74 | -916.30 | -2,7% | |
| 2025-04-04 | Paulson Richard A. | Director, Officer, President and CEO | Open Market Sale | -245 | 3.74 | -916.30 | -2,7% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.